A carregar...
Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?
The current therapeutic landscape of luminal human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (mBC) is fundamentally evolving, particularly in the advent of molecularly targeted therapies, such as inhibitors of mammalian target of rapamycin and cyclin-dependent kinas...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6295674/ https://ncbi.nlm.nih.gov/pubmed/30574210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918815591 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|